New data from Novavax’s ongoing research on its updated XBB.1.5 COVID-19 vaccine in participants who previously received an mRNA vaccine showed robust neutralizing antibody titers for the XBB.1.5 subvariant as well as for the currently circulating JN.1 subvariant. Data also showed that the vaccine’s safety and reactogenicity profile was consistent with its prototype vaccine (NVX-CoV2373).
Differences observed in immunoglobulin (IgG) subclass responses and Fc?-mediated effector functions following mRNA and protein-based COVID-19 vaccinations will be shared.
https://www.terrapinn.com/conference/world-vaccine-congress-washington/index.stm
